Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have shown effectiveness for advanced non-small-cell lung cancer (NSCLC) with activating mutations in the EGFR gene. However, resistance to the EGFR TKIs develops mostly secondary to T790M mutation in exon 20. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro Gomes, Jéssica, Cruz, Marcelo Rocha S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446010/
https://www.ncbi.nlm.nih.gov/pubmed/26056478
http://dx.doi.org/10.2147/OTT.S75388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446010/
https://www.ncbi.nlm.nih.gov/pubmed/26056478
http://dx.doi.org/10.2147/OTT.S75388

Ejemplares similares